doi: 10.3389/fphys.2019.00961 54
Future GLP-1 drugs can be purpose-built for the brain
Additionally, clinical trials with long-acting dual or triple agonists targeting the glucagon receptor have demonstrated a marked suppressive effect on circulating amino-acids in both humans and animals [66, 67]
During the opening lecture at the International Conference on Advanced Technologies & Treatments for Diabetes, Melanie Davies, CBE, MB, ChB, MD, FRCP, FRCGP, professor of diabetes medicine at the University of Leicester and an honorary consultant diabetologist at the University Hospitals of Leicester NHS Trust, reviewed how GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy, Novo Nordisk) have changed the way providers approach the treatment of type 2 diabetes and obesity and discussed some of the medications that combine GLP-1 with other molecules
Do not assume that a medication should be restarted at the same dose after a treatment gap
We make our sublingual suspension using Semaglutide base which is purchased from an FDA registered facility